摘要
目的:探讨套细胞淋巴瘤(MCL)患者的临床特点、治疗与疗效的关系。方法:回顾分析我院16例MCL患者的临床资料,采用MCL国际预后指数(MIPI)和MIPIb(Ki-67)评估,观察短期缓解率和长期疗效,包括2年总生存率及无进展生存率(PFS),分析临床因素对预后的影响。结果:16例患者中,男10例,女6例,男∶女约为3∶2,临床分期Ⅲ~Ⅳ期约占93.8%,所有患者均接受1个疗程以上的CHOP(E)±美罗华(R)等方案化疗。预后因素分析发现:①虽然MIPI〈5.7、Ki-67≤40%、β2-GM〈3mg/L各组患者分别与MIPI≥5.7、Ki-67〉40%、β2-GM≥3mg/L各组患者的短期缓解率无明显差异,但前3个组患者2年PFS率分别明显高于后3个组(66.7%∶25.0%,63.6%∶19.1%,78.9%∶33.5%,均P〈0.05);②9例检测SOX-11,阳性率66.7%(6/9),未发现预后相关性;③CHOP(E)+R与PAD方案组的短期完全缓解率及2年PFS率均明显优于CHOP(E)方案组(57.1%∶100%∶0,71.4%∶100%∶11.1%,均P〈0.05);④难治/复发患者中,1例行自体造血干细胞移植及2例行含硼替佐米的PAD方案化疗,均获得长期PFS。结论:MCL患者男性多发,多为Ⅲ~Ⅳ期,MIPI指数、Ki-67、β2-GM对临床预后判断有重要作用;SOX-11预后相关性有待深入研究;CHOP(E)+R较CHOP(E)疗效好,PAD方案联合美罗华维持治疗对难治/复发患者的疗效显著,有待进一步临床观察。
Objective:To investigate the relationship between the clinical characteristics,therapy and curative efficacy of mantle cell lymphoma(MCL)patients in our hospital.Method:Clinical data of 16MCL patients in our hospital has been retrospectively analyzed.We used MCL international prognostic index(MIPI),MIPI-biological(Ki-67)and observed the short-term remission rate and long-term curative effect including 2years overall survival and progression-free survival(PFS)to analyze the clinical prognostic factors.Result:Among the 16patients,the ratio of male to female was 3∶2.Ninety-three point eight percentage of MCL patients were in Ann Arbor stageⅢtoⅣ who had received more than one cycles of CHOP(E)±R chemotherapy.After analyze the clinical factors,we found that:①Respectively compared the three groups of MIPI5.7,Ki-67≤40%andβ2-GM3mg/L with the three groups of MIPI≥5.7,Ki-6740% andβ2-GM≥3mg/L,the short-term remission rates had no significant difference,while the 2years PFS of the previous three groups were longer than that of the posterior three groups(66.7%vs 25.0%,63.6%vs 19.1%,78.9%vs 33.5%,P〈0.05).②SOX-11protein has been detected in nine cases and 66.7%of cases were positive without prognosis-associated relationship.③The complete remission rate and the 2years PFS of CHOP(E)+R and PAD regimen were superior to those of the CHOP(E)regimen(57.1%vs 100%vs 0,71.4%vs 100%vs 11.1%,P〈0.05).④Among three relapsed/refractory MCL patients,one who was treated with autologous peripheral blood stem cell transplantation and the other two who were received PAD regimen chemotherapy all had long-term PFS.Conclusion:Most patients with MCL were male and usually in Ann Arbor stageⅢtoⅣ.MIPI,Ki-67andβ2-GM play an important role in prediction of MCL prognosis.SOX-11in prognosis of MCL still needs to be made an intensive study.CHOP(E)+R regimen is more effective than CHOP(E).Curative effect of PAD regimen combined maintenance rituximab for refractory/relapse cases is distinct which remains to be further clinical observed.
出处
《临床血液学杂志》
CAS
2014年第4期593-596,599,共5页
Journal of Clinical Hematology
关键词
淋巴瘤
套细胞
诊断
治疗
mantle cell lymphoma
diagnosis
therapy